Document is current
Any future updates will be listed below
-
Authors
Morel, Daphné https://orcid.org/0000-0002-9121-4973
Jeffery, Daniel https://orcid.org/0000-0003-2289-8379
Aspeslagh, Sandrine
Almouzni, Geneviève https://orcid.org/0000-0001-5570-0723
Postel-Vinay, Sophie https://orcid.org/0000-0001-5562-1857
- License Information
-
More Information
Article History
Accepted: 13 August 2019
First Online: 30 September 2019
Competing interests
: As part of the Drug Development Department (DITEP), S.P.-V. has been a principal/sub-investigator of clinical trials for Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer, Beigene, Bioalliance Pharma, Biontech, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, Clovis Oncology, Daiichi Sankyo, Debiopharm, Eisai, Exelixis, Forma, Gamamabs, Genentech, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, H3 Biomedicine, Hoffmann-La Roche, Incyte, Innate Pharma, Iris Servier, Janssen, Kura Oncology, Kyowa Kirin, Lilly, Loxo Oncology, Lytix Biopharma, MedImmune, Menarini Ricerche, Merck Sharp & Dohme-Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, PharmaMar, Pierre Fabre, Rigontec, Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Tioma Therapeutics, to-BBB Technologies BV and Xencor. S.P.-V. has received research grants from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche and Sanofi, as well as non-financial research support (provision of drugs) from Astrazeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Johnson & Johnson, Lilly, MedImmune, Merck, NH TherAGuiX, Pfizer and Roche. S.P.-V. has also received research funding from Boehringer Ingelheim, Merck and Roche for research projects unrelated to this manuscript. S.P.-V. has participated on advisory boards for Merck and has benefited from non-financial support for attending symposia (travel paid and congress registration) from AstraZeneca. D.M., D.J., S.A. and G.A. declare no competing interests.
